CAMBRIDGE, Mass .– (COMMERCIAL THREAD) –Moderna, Inc. (Nasdaq: MRNA), a pioneering biotechnology company in messenger RNA (mRNA) therapies and vaccines, today announced that it will build a state-of-the-art mRNA facility in Africa with the aim of produce up to 500 million doses of vaccine each year at the 50 Âµg dose level. The company plans to invest up to $ 500 million in this new facility which is expected to include the manufacture of drug substances with the ability to fill / finish and condition capacities on site. The company plans to launch a country and site selection process soon.
âSince Moderna was founded in 2010, our mission has been to make a transformative impact on human lives through our medicines. After a decade of pioneering the development of our mRNA platform, we have been honored to play a pivotal role in the fight against the COVID-19 pandemic on a global scale with our mRNA vaccine. We believe that Moderna’s work has only just begun, âsaid StÃ©phane Bancel, CEO of Moderna. âOn behalf of our growing team, partners and shareholders, we are determined to extend Moderna’s societal impact by investing in a state-of-the-art mRNA manufacturing facility in Africa. While we are still working to increase the capacity of our current network to deliver vaccines for the ongoing pandemic in 2022, we believe it is important to invest in the future. We plan to manufacture our COVID-19 vaccine as well as additional products within our mRNA vaccine portfolio at this facility. ”
Moderna and its partners have increased their capacity worldwide and to date have provided more than 500 million doses of Moderna’s COVID-19 vaccine. As recently announced, several efforts are being made to continue increasing capacity at a significant rate. This announcement is a new investment to add a manufacturing site in Africa to Moderna’s expanding global network.
Moderna pipeline includes 20 vaccine candidates in its prophylactic vaccine modality, including vaccines against respiratory viruses, vaccines against latent viruses and vaccines against threats to global public health.
In the 10 years since its inception, Moderna has grown from a company in the scientific research stage advancing programs in the field of messenger RNA (mRNA), to a company with a diverse clinical portfolio of vaccines and therapeutic products. through six modalities, a broad portfolio of intellectual property in areas such as the formulation of mRNA and lipid nanoparticles, and an integrated manufacturing facility that enables large-scale clinical and commercial production at unprecedented speed. Moderna maintains alliances with a wide range of domestic and foreign government and business collaborators, which has allowed the pursuit of both groundbreaking science and rapid scale up of manufacturing. More recently, Moderna’s capabilities have come together to enable the licensed use of one of the oldest and most effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advancements in basic and applied mRNA science, delivery technology and manufacturing, and has enabled the development of therapies and vaccines for them. infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases. Moderna was named one of the top biopharmaceutical employers by Science for six years. To learn more, visit www.modernatx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, in particular concerning: the Company’s plans to invest in an mRNA-based drug manufacturing plant in Africa ; the production scale of this manufacturing facility; and the total investment in the facility. The forward-looking statements contained in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve risks, uncertainties and other known and unknown factors, many of which are beyond Moderna’s control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include the other risks and uncertainties described under the heading “Risk Factors” in Moderna’s most recent annual report on Form 10-K filed with the State Securities and Exchange Commission (SEC). United and in subsequent filings by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility to update or revise any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of the date hereof.